Company Encyclopedia
View More
name
Mural Oncology
MURA.US
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs.
1.930 T
MURA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

    XOMA Royalty Corporation has completed its acquisition of Mural Oncology plc, sanctioned by the Irish High Court. Mural shareholders received $2.035 per share, and Mural's shares will be delisted from Nasdaq. Legal and financial advisors were involved in the transaction. XOMA Royalty, a biotech royalty aggregator, aims to improve human health by acquiring future economics of therapeutic candidates.

    fidelity·
    US
    MURA
    0.00%
    US
    XOMA
    -3.92%
    fidelity·
    US
    MURA
    0.00%
    US
    XOMA
    -3.92%

    REG - Irish Takeover Panel - Disclosure Table

    The Irish Takeover Panel has disclosed that Mural Oncology plc, Avadel Pharmaceuticals plc, and Permanent TSB Group Holdings plc are in an offer period. Mural Oncology's offeror is XOMA Royalty Corporation, and Avadel Pharmaceuticals' offeror is Alkermes plc. Permanent TSB Group Holdings has no identified offeror. This disclosure is part of the rules of the Irish Takeover Panel, with no specific Rule 2.6(a) deadlines provided for these companies.

    London Stock Exchange·
    US
    MURA
    0.00%
    US
    AVDL
    -0.07%
    London Stock Exchange·
    US
    MURA
    0.00%
    US
    AVDL
    -0.07%

    Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition | MURA Stock News

    Mural Oncology plc announced the effectiveness of its scheme of arrangement, leading to its acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation. The acquisition involves the entire issued share capital of Mural. The distribution of cash consideration to shareholders is expected to commence soon, with completion by December 19, 2025. Mural's shares have been delisted from the Nasdaq Global Market as of December 4, 2025. Forward-looking statements caution about potential risks and uncertainties.

    StockTitan·
    US
    MURA
    0.00%
    StockTitan·
    US
    MURA
    0.00%

    REG - Citadel Group Mural Oncology PLC - Form 8.3 - Mural Oncology plc

    Citadel Group has made an opening position disclosure under Rule 8.3 of the Irish Takeover Panel Act, 1997, concerning Mural Oncology PLC. The disclosure includes interests and short positions in relevant securities, with Citadel owning 1.65% of common stock. Various transactions in securities are detailed, including purchases and sales. No indemnity or option arrangements are reported. A Supplemental Form 8 is attached.

    London Stock Exchange·
    US
    MURA
    0.00%
    London Stock Exchange·
    US
    MURA
    0.00%

    REG - Oddo BHF AIF PLC Mural Oncology PLC - Form 8.3 - Mural Oncology plc

    Oddo BHF AIF PLC has made a disclosure under Rule 8.3 of the Irish Takeover Panel Act, 1997, regarding its interests in Mural Oncology PLC. The disclosure includes details of relevant securities owned, cash-settled derivatives, and stock-settled derivatives. Oddo BHF AIF PLC owns 603,000 securities, representing 3.48% of Mural Oncology PLC. No supplemental Form 8.3 is attached.

    London Stock Exchange·
    US
    MURA
    0.00%
    London Stock Exchange·
    US
    MURA
    0.00%
    © 2025 Longbridge｜Disclaimer